Recent advances in the understanding and treatment of acute myeloid leukemia

doi:10.12688/f1000research.14116.1

Review

. 2018 Aug 6:7:F1000 Faculty Rev-1196.

doi: 10.12688/f1000research.14116.1. eCollection 2018.

Recent advances in the understanding and treatment of acute myeloid leukemia

Justin Watts¹, Stephen Nimer¹

Affiliations

PMID: 30135719
PMCID: PMC6081972
DOI: 10.12688/f1000research.14116.1

Review

Recent advances in the understanding and treatment of acute myeloid leukemia

Justin Watts et al. F1000Res. 2018.

. 2018 Aug 6:7:F1000 Faculty Rev-1196.

doi: 10.12688/f1000research.14116.1. eCollection 2018.

Authors

Justin Watts¹, Stephen Nimer¹

Affiliation

¹ Sylvester Comprehensive Cancer Center and Miller School of Medicine, University of Miami, Miami, Florida, USA.

PMID: 30135719
PMCID: PMC6081972
DOI: 10.12688/f1000research.14116.1

Abstract

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals.

Keywords: acute myeloid leukemia (AML); genomics; epigenetics; targeted therapies; drug development.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Justin Watts has served as a consultant and on the Speaker’s Bureau for Jazz Pharmaceuticals. He has received research funding from Takeda.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

Cited by

Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F, Anekpuritanang T, Press RD. Yang F, et al. Mol Diagn Ther. 2020 Feb;24(1):1-13. doi: 10.1007/s40291-019-00443-9. Mol Diagn Ther. 2020. PMID: 31848884 Review.
A tubulin binding molecule drives differentiation of acute myeloid leukemia cells.
Jackson TR, Vuorinen A, Josa-Culleré L, Madden KS, Conole D, Cogswell TJ, Wilkinson IVL, Kettyle LM, Zhang D, O'Mahony A, Gracias D, McCall L, Westwood R, Terstappen GC, Davies SG, Tate EW, Wynne GM, Vyas P, Russell AJ, Milne TA. Jackson TR, et al. iScience. 2022 Jul 19;25(8):104787. doi: 10.1016/j.isci.2022.104787. eCollection 2022 Aug 19. iScience. 2022. PMID: 35992086 Free PMC article.
De-novo acute myeloid leukemia in a BRCA positive female with locally treated ductal carcinoma In Situ.
Nabrinsky E, Masood F, AbdulMujeeb S, Asado N, Almanaseer I, Galvez A. Nabrinsky E, et al. Leuk Res Rep. 2021 Feb 9;15:100237. doi: 10.1016/j.lrr.2021.100237. eCollection 2021. Leuk Res Rep. 2021. PMID: 33665080 Free PMC article.
DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia.
Golla U, Ehudin MA, Annageldiyev C, Zeng Z, Bastihalli Tukaramrao D, Tarren A, Date AA, Elcheva I, Berg A, Amin S, Loughran TP Jr, Kester M, Desai D, Dovat S, Claxton D, Sharma A. Golla U, et al. Cancers (Basel). 2021 Sep 29;13(19):4889. doi: 10.3390/cancers13194889. Cancers (Basel). 2021. PMID: 34638385 Free PMC article.
Distribution of fusion transcripts and its clinical impact in patients with acute myeloid leukemia in Sudan.
Muddathir ARM, Hamid TAM, Elamin EM, Khabour OF. Muddathir ARM, et al. Int J Health Sci (Qassim). 2021 Mar-Apr;15(2):21-25. Int J Health Sci (Qassim). 2021. PMID: 33708041 Free PMC article.

See all "Cited by" articles

References

1. https://seer.cancer.gov/statfacts/html/amyl.html
1. Juliusson G, Antunovic P, Derolf A, et al. : Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–87. 10.1182/blood-2008-07-172007 - DOI - PubMed
2. F1000 Recommendation
1. Slovak ML, Kopecky KJ, Cassileth PA, et al. : Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075–83. - PubMed
1. Tallman MS, Gilliland DG, Rowe JM: Drug therapy for acute myeloid leukemia. Blood. 2005;106(4):1154–63. 10.1182/blood-2005-01-0178 - DOI - PubMed
1. Burnett AK, Milligan D, Goldstone A, et al. : The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol. 2009;145(3):318–32. 10.1111/j.1365-2141.2009.07604.x - DOI - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] https://seer.cancer.gov/statfacts/html/amyl.html

[2] https://seer.cancer.gov/statfacts/html/amyl.html

[3] Juliusson G, Antunovic P, Derolf A, et al. : Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–87. 10.1182/blood-2008-07-172007 - DOI - PubMed

F1000 Recommendation

[4] Juliusson G, Antunovic P, Derolf A, et al. : Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–87. 10.1182/blood-2008-07-172007 - DOI - PubMed

[5] F1000 Recommendation

[6] Slovak ML, Kopecky KJ, Cassileth PA, et al. : Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075–83. - PubMed

[7] Slovak ML, Kopecky KJ, Cassileth PA, et al. : Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075–83. - PubMed

[8] Tallman MS, Gilliland DG, Rowe JM: Drug therapy for acute myeloid leukemia. Blood. 2005;106(4):1154–63. 10.1182/blood-2005-01-0178 - DOI - PubMed

[9] Tallman MS, Gilliland DG, Rowe JM: Drug therapy for acute myeloid leukemia. Blood. 2005;106(4):1154–63. 10.1182/blood-2005-01-0178 - DOI - PubMed

[10] Burnett AK, Milligan D, Goldstone A, et al. : The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol. 2009;145(3):318–32. 10.1111/j.1365-2141.2009.07604.x - DOI - PubMed

[11] Burnett AK, Milligan D, Goldstone A, et al. : The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol. 2009;145(3):318–32. 10.1111/j.1365-2141.2009.07604.x - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Recent advances in the understanding and treatment of acute myeloid leukemia

Affiliation

Recent advances in the understanding and treatment of acute myeloid leukemia

Authors

Affiliation

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical